Masebole Masenya
University Medical Center Utrecht(NL)
Publications by Year
Research Areas
HIV/AIDS drug development and treatment, SARS-CoV-2 and COVID-19 Research, COVID-19 Clinical Research Studies, HIV/AIDS Research and Interventions, HIV-related health complications and treatments
Most-Cited Works
- → Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant(2021)1,318 cited
- → Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV(2019)698 cited
- → Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants(2020)414 cited
- → Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial(2020)254 cited
- → Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial(2021)159 cited
- → Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B.1.351 variant in South Africa(2021)122 cited
- → Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial(2021)43 cited
- → Final 192-Week Efficacy and Safety Results of the ADVANCE Trial, Comparing 3 First-line Antiretroviral Regimens(2024)31 cited
- → The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz(2021)19 cited
- → ChAdOx1 nCoV-19 (AZD1222) Vaccine in People Living With and Without HIV(2021)9 cited